• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer.

作者信息

Li Jianbing, Hao Chunfang, Wang Haibo, Pan Yueyin, Jiang Zefei

机构信息

Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing, China.

Department of Oncology, Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.

出版信息

Transl Breast Cancer Res. 2025 Jul 23;6:28. doi: 10.21037/tbcr-25-35. eCollection 2025.

DOI:10.21037/tbcr-25-35
PMID:40756960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12314678/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1891/12314678/7d3d5bb9233d/tbcr-06-28-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1891/12314678/f72c92b654f2/tbcr-06-28-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1891/12314678/cfbcf33ddad1/tbcr-06-28-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1891/12314678/7d3d5bb9233d/tbcr-06-28-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1891/12314678/f72c92b654f2/tbcr-06-28-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1891/12314678/cfbcf33ddad1/tbcr-06-28-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1891/12314678/7d3d5bb9233d/tbcr-06-28-f3.jpg

相似文献

1
DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer.DESTINY-Breast09，HER2阳性晚期乳腺癌一线治疗的新突破。
Transl Breast Cancer Res. 2025 Jul 23;6:28. doi: 10.21037/tbcr-25-35. eCollection 2025.
2
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.研究总结：通过纳入HER2免疫组化状态分析曲妥珠单抗德鲁替康在HER2表达实体瘤中的疗效：DESTINY-PanTumor02的事后分析
Adv Ther. 2025 May;42(5):2015-2018. doi: 10.1007/s12325-024-03080-9. Epub 2025 Mar 6.
3
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.曲妥珠单抗德鲁昔单抗治疗激素受体阳性、HER2低表达或HER2极低表达转移性乳腺癌的患者报告结局：随机DESTINY-Breast06试验结果
ESMO Open. 2025 May;10(5):105082. doi: 10.1016/j.esmoop.2025.105082. Epub 2025 May 15.
4
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.DESTINY-Breast Respond HER2-low 欧洲研究设计：T-DXd 在 HER2 低表达晚期乳腺癌患者中的应用。
Future Oncol. 2024;20(18):1237-1250. doi: 10.2217/fon-2024-0015. Epub 2024 Apr 9.
5
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.曲妥珠单抗-德曲妥珠单抗治疗既往治疗的 HER2 阳性转移性乳腺癌：DESTINY-Breast01 研究的通俗易懂摘要。
Future Oncol. 2021 Sep 1;17(26):3415-3423. doi: 10.2217/fon-2021-0427. Epub 2021 Jul 15.
6
Real-Life Experience of HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Advanced Breast Cancer Patients Treated With T-DXd (Trastuzumab Deruxtecan): A Multicentric Portuguese Study.T-DXd（曲妥珠单抗德鲁昔单抗）治疗HER2（人表皮生长因子受体2）阳性晚期乳腺癌患者的真实世界经验：一项葡萄牙多中心研究。
Cureus. 2025 Feb 27;17(2):e79734. doi: 10.7759/cureus.79734. eCollection 2025 Feb.
7
Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab.曲妥珠单抗德鲁昔单抗用于激素受体阳性/人表皮生长因子受体2低表达乳腺癌骨转移患者：地诺单抗增强疗效。
Transl Breast Cancer Res. 2025 May 6;6:25. doi: 10.21037/tbcr-24-50. eCollection 2025.
8
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.在一个大型转移性乳腺癌患者真实世界数据库中，根据生物标志物状态、治疗线数和既往是否接受过戈沙妥珠单抗，分析曲妥珠单抗德鲁替康的治疗结果。
ESMO Open. 2025 Jun 17;10(7):105330. doi: 10.1016/j.esmoop.2025.105330.
9
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.在 III 期 DESTINY-Breast03 研究中，接受曲妥珠单抗 deruxtecan 或曲妥珠单抗 emtansine 的 HER2 阳性转移性乳腺癌患者的患者报告结局和住院数据。
Ann Oncol. 2023 Jul;34(7):569-577. doi: 10.1016/j.annonc.2023.04.516. Epub 2023 May 12.
10
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.DESTINY-Breast04研究中患者报告的结局：曲妥珠单抗德鲁昔单抗与HER2低表达转移性乳腺癌患者的医生选择的化疗对比
Oncologist. 2025 May 8;30(5). doi: 10.1093/oncolo/oyaf048.

本文引用的文献

1
Overall Survival with Inavolisib in -Mutated Advanced Breast Cancer.Inavolisib用于PIK3CA突变的晚期乳腺癌的总生存期
N Engl J Med. 2025 Jul 10;393(2):151-161. doi: 10.1056/NEJMoa2501796. Epub 2025 May 31.
2
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China.2024年中国临床肿瘤学会乳腺癌（CSCO BC）指南：来自中国的国际贡献。
Cancer Biol Med. 2024 Oct 21;21(10):838-43. doi: 10.20892/j.issn.2095-3941.2024.0374.
3
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
吡咯替尼对比安慰剂联合曲妥珠单抗和多西他赛用于治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者（PHILA）：一项随机、双盲、多中心、III 期临床试验。
BMJ. 2023 Oct 31;383:e076065. doi: 10.1136/bmj-2023-076065.
4
Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021.中国和美国 2011 至 2021 年早期乳腺癌患者治疗差异和转变趋势。
JAMA Netw Open. 2023 Jun 1;6(6):e2321388. doi: 10.1001/jamanetworkopen.2023.21388.
5
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.帕妥珠单抗、曲妥珠单抗和多西他赛用于治疗既往未接受治疗的人表皮生长因子受体 2（HER2）阳性局部复发或转移性乳腺癌的中国患者（PUFFIN）：一项随机、双盲、安慰剂对照的 III 期研究的最终分析。
Breast Cancer Res Treat. 2023 Feb;197(3):503-513. doi: 10.1007/s10549-022-06775-1. Epub 2022 Dec 4.
6
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
7
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.抗 ERBB2 抗体药物偶联物所致间质性肺病：综述。
JAMA Oncol. 2021 Dec 1;7(12):1873-1881. doi: 10.1001/jamaoncol.2021.3595.
8
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.帕妥珠单抗、曲妥珠单抗和多西他赛联合用于治疗人表皮生长因子受体 2（HER2）阳性转移性乳腺癌（CLEOPATRA）：一项双盲、随机、安慰剂对照、3 期研究的终期结果。
Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
9
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.曲妥珠单抗恩美曲妥珠单抗联合或不联合帕妥珠单抗对比曲妥珠单抗联合紫杉烷用于人表皮生长因子受体2阳性晚期乳腺癌：III期MARIANNE研究的主要结果
J Clin Oncol. 2017 Jan 10;35(2):141-148. doi: 10.1200/JCO.2016.67.4887. Epub 2016 Nov 7.
10
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.帕妥珠单抗、曲妥珠单抗和多西他赛用于HER2阳性转移性乳腺癌的治疗
N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.